CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Inclusion Criteria: 1. The subject voluntarily participates in the clinical study; Fully understand and be Informed of the study and sign the Informed consent (Informed Consent Form, ICF)（For minors, the guardian shall also provide written informed consent ）; Willing to follow and able to complete all test procedures; Informed consent must be obtained before initiating any tests or procedures related to the study that are not part of the standard treatment of the subject's disease; 2. Age 14-60 years; 3. ECOG score: ≤2; 4. Relapsed/refractory AML must meet one of the following conditions: 1. Twice or more relapse; 2. Newly diagnosed AML patients who failed after 2 cycles of standard chemotherapy; 3. Relapse within 12 months after CR, or relapse after 12 months with CR but failed to respond to conventional chemotherapy; 4. Persistent extramedullary leukemia. 5. Meet the requirements of allogeneic HSCT 6. Expected survival ≥ 3 months; Exclusion Criteria: 1. Subject with APL/AML-M3:t(15;17)(q22;q12) 2. Received any of the following treatments: * Previous allo-HSCT(Subjects who received allo-HSCT for more than 6 months, have stopped immunosuppressive drugs and have no active GvHD are not included in the exclusion criteria) * Previous gene therapy * Previous anti CD33/CLL1 therapy * Previous any target CAR-T cells therapy 3. Prior antitumor therapy with insufficient washout period; 4. CNS infiltration; Except for patients with prior CNS infiltration who are currently in remission; 5. HBsAg, HBV DNA, HCV-Ab, HCV RNA or HIV-Ab positive; 6. Pregnant or breast-feeding women;